|Bid||15.01 x 900|
|Ask||18.03 x 1300|
|Day's Range||17.45 - 18.05|
|52 Week Range||13.04 - 32.88|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.75|
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3.
– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716.
HAMILTON, Bermuda, Feb. 28, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Cowen and Company 39th Annual Healthcare Conference.
HAMILTON, Bermuda, Feb. 26, 2019 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Barclays Global Healthcare Conference on Tuesday,.
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”, “we”, and “our”) announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per share, before underwriting discounts and commissions. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 398,247 additional Class A common shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on February 4, 2019, subject to customary closing conditions.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 28) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional Class A common shares. All of the Class A common shares are being offered by Kiniksa.
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a clinical study of mavrilimumab in subjects with giant cell arteritis (GCA). U.S. subjects will be included in the ongoing, global Phase 2 clinical trial, in which dosing has already commenced in multiple countries.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...